Overcoming Chemotherapy Resistance in Metastatic Cancer: A Comprehensive Review

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 Jan 23

PMID 38255288

Authors

Maryam Eslami

Omid Memarsadeghi

Ali Davarpanah

Afshin Arti

Karim Nayernia

Babak Behnam

Affiliations

Soon will be listed here.

Abstract

The management of metastatic cancer is complicated by chemotherapy resistance. This manuscript provides a comprehensive academic review of strategies to overcome chemotherapy resistance in metastatic cancer. The manuscript presents background information on chemotherapy resistance in metastatic cancer cells, highlighting its clinical significance and the current challenges associated with using chemotherapy to treat metastatic cancer. The manuscript delves into the molecular mechanisms underlying chemotherapy resistance in subsequent sections. It discusses the genetic alterations, mutations, and epigenetic modifications that contribute to the development of resistance. Additionally, the role of altered drug metabolism and efflux mechanisms, as well as the activation of survival pathways and evasion of cell death, are explored in detail. The strategies to overcome chemotherapy resistance are thoroughly examined, covering various approaches that have shown promise. These include combination therapy approaches, targeted therapies, immunotherapeutic strategies, and the repurposing of existing drugs. Each strategy is discussed in terms of its rationale and potential effectiveness. Strategies for early detection and monitoring of chemotherapy drug resistance, rational drug design vis-a-vis personalized medicine approaches, the role of predictive biomarkers in guiding treatment decisions, and the importance of lifestyle modifications and supportive therapies in improving treatment outcomes are discussed. Lastly, the manuscript outlines the clinical implications of the discussed strategies. It provides insights into ongoing clinical trials and emerging therapies that address chemotherapy resistance in metastatic cancer cells. The manuscript also explores the challenges and opportunities in translating laboratory findings into clinical practice and identifies potential future directions and novel therapeutic avenues. This comprehensive review provides a detailed analysis of strategies to overcome chemotherapy resistance in metastatic cancer. It emphasizes the importance of understanding the molecular mechanisms underlying resistance and presents a range of approaches for addressing this critical issue in treating metastatic cancer.

Citing Articles

Biological Activity of Peptide Fraction Derived from L. (Diptera: Stratiomyidae) Larvae Haemolymph on Gastric Cancer Cells.

Rinaldi R, Laurino S, Salvia R, Russi S, De Stefano F, Galasso R Int J Mol Sci. 2025; 26(5).

PMID: 40076512 PMC: 11899352. DOI: 10.3390/ijms26051885.

Synthesis, Anticancer Screening, and In Silico Evaluations of Thieno[2,3-]pyridine Derivatives as Hsp90 Inhibitors.

Chandrasekaran B, Bayan M, Hmedat A, Al-Jaidi B, Al-Tawalbeh D, Abuarqoub D Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40005967 PMC: 11858597. DOI: 10.3390/ph18020153.

Prediction of Pt, Ir, Ru, and Rh complexes light absorption in the therapeutic window for phototherapy using machine learning.

Vigna V, Cova T, Pais A, Sicilia E J Cheminform. 2025; 17(1):1.

PMID: 39757232 PMC: 11702227. DOI: 10.1186/s13321-024-00939-5.

Coptisine enhances the sensitivity of chemoresistant breast cancer cells by inhibiting the function and expression of ABC transporters.

Eid S Front Pharmacol. 2024; 15:1472458.

PMID: 39691399 PMC: 11650208. DOI: 10.3389/fphar.2024.1472458.

Recent advancements and clinical aspects of engineered iron oxide nanoplatforms for magnetic hyperthermia-induced cancer therapy.

Rajan A, Laha S, Sahu N, Thorat N, Shankar B Mater Today Bio. 2024; 29:101348.

PMID: 39669801 PMC: 11636219. DOI: 10.1016/j.mtbio.2024.101348.

References

Navarro G, Sawant R, Biswas S, Essex S, Tros de Ilarduya C, Torchilin V . P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Nanomedicine (Lond). 2011; 7(1):65-78. PMC: 3422569. DOI: 10.2217/nnm.11.93. View

Wang Q, Zhou W . Roles and molecular mechanisms of physical exercise in cancer prevention and treatment. J Sport Health Sci. 2020; 10(2):201-210. PMC: 7987556. DOI: 10.1016/j.jshs.2020.07.008. View

Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F . Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica. 2015; 101(3):346-55. PMC: 4815726. DOI: 10.3324/haematol.2015.135780. View

Maeng Y, Lee R, Lee B, Choi S, Kim E . Lithium inhibits tumor lymphangiogenesis and metastasis through the inhibition of TGFBIp expression in cancer cells. Sci Rep. 2016; 6:20739. PMC: 4746585. DOI: 10.1038/srep20739. View

Bielawski K, Winnicka K, Bielawska A . Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A. Biol Pharm Bull. 2006; 29(7):1493-7. DOI: 10.1248/bpb.29.1493. View

Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T . The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells. Leukemia. 2007; 22(3):635-8. DOI: 10.1038/sj.leu.2404922. View

Ding S, Hsu C, Wang Z, Natesh N, Millen R, Negrete M . Patient-derived micro-organospheres enable clinical precision oncology. Cell Stem Cell. 2022; 29(6):905-917.e6. PMC: 9177814. DOI: 10.1016/j.stem.2022.04.006. View

Jin N, George T, Otterson G, Verschraegen C, Wen H, Carbone D . Advances in epigenetic therapeutics with focus on solid tumors. Clin Epigenetics. 2021; 13(1):83. PMC: 8056722. DOI: 10.1186/s13148-021-01069-7. View

Ouyang L, Shi Z, Zhao S, Wang F, Zhou T, Liu B . Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012; 45(6):487-98. PMC: 6496669. DOI: 10.1111/j.1365-2184.2012.00845.x. View

10.

You M, Varona-Santos J, Singh S, Robbins D, Savaraj N, Nguyen D . Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg. 2013; 147(1):508-16. DOI: 10.1016/j.jtcvs.2013.08.035. View

11.

Goossens N, Nakagawa S, Sun X, Hoshida Y . Cancer biomarker discovery and validation. Transl Cancer Res. 2015; 4(3):256-269. PMC: 4511498. DOI: 10.3978/j.issn.2218-676X.2015.06.04. View

12.

Holien T, Olsen O, Misund K, Hella H, Waage A, Ro T . Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate. Eur J Haematol. 2013; 91(4):339-46. DOI: 10.1111/ejh.12176. View

13.

Cree I, Glaysher S, Harvey A . Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol. 2010; 10(4):375-9. DOI: 10.1016/j.coph.2010.05.001. View

14.

Klibanov A, Maruyama K, Torchilin V, Huang L . Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990; 268(1):235-7. DOI: 10.1016/0014-5793(90)81016-h. View

15.

Durlacher C, Chow K, Chen X, He Z, Zhang X, Yang T . Targeting Na⁺/K⁺ -translocating adenosine triphosphatase in cancer treatment. Clin Exp Pharmacol Physiol. 2015; 42(5):427-43. DOI: 10.1111/1440-1681.12385. View

16.

Daley E, Wilkie D, Loesch A, Hargreaves I, Kendall D, Pilkington G . Chlorimipramine: a novel anticancer agent with a mitochondrial target. Biochem Biophys Res Commun. 2005; 328(2):623-32. DOI: 10.1016/j.bbrc.2005.01.028. View

17.

Shimizu T, LoRusso P, Papadopoulos K, Patnaik A, Beeram M, Smith L . Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors. Clin Cancer Res. 2014; 20(19):5032-40. DOI: 10.1158/1078-0432.CCR-14-0570. View

18.

Longley D, Johnston P . Molecular mechanisms of drug resistance. J Pathol. 2005; 205(2):275-92. DOI: 10.1002/path.1706. View

19.

Pramanik D, Campbell N, Das S, Gupta S, Chenna V, Bisht S . A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. Oncotarget. 2012; 3(6):640-50. PMC: 3442295. DOI: 10.18632/oncotarget.543. View

20.

Schuyer M, van der Burg M, Henzen-Logmans S, Fieret J, Klijn J, Look M . Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer. 2001; 85(9):1359-67. PMC: 2375252. DOI: 10.1054/bjoc.2001.2101. View